Endocrine Abstracts

Pasireotide, a multireceptor-targeted somatostatin analogue, was approved for the treatment of acromegaly, after being studied in two large, randomised, multi-center clinical trials. We reported the history of a 76 years old man affected by acromegaly, treated with Pasireotide long acting release (LAR) as first line therapy. Acromegaly was diagnosed in 2009, as the result of endocrinological investigation suggested by altered facial appearance and macroglossia. Hormonal assays...

IntroductionPrimary autoimmune hypophysitis (PAHs) is a rare inflammatory disease of the pituitary gland. Although largely investigated, the pathogenesis of PAH is not completely clarified. We aimed to investigate the immune response in PAHs.Material and methodsSerum anti-pituitary and anti-hypothalamus antibodies (respectively APAs and AHAs) were investigated though an indirect immunofluorescence on monkey h...

Introduction: Bilateral sampling of the inferior petrosal sinuses (IPSS) is considerate actually the best diagnostic test for Cushing.Patients and methods: We retrospectively reviewed our series of patients undergone IPSS for Cushing disease and we compared the difference between central and peripheral ACTH gradient in basal condition and after CRH stimulation in cases of localization of the tip of the catheters inside the inferior petrosal sinus or at t...

Introduction: A significant number of GH-secreting pituitary adenomas show an aggressive behavior, therefore, when uncontrolled acromegaly persists, a pharmaceutical combination may improve biochemical control, with reduction of disease morbidity and mortality. We aimed to describe the clinical features of four patients successfully treated with a pharmacological combination of pasireotide LAR, pegvisomant and cabergoline.Case reports: Acromegaly was dia...

Purpose: Primary hypophysitis is a rare disease, with an autoimmune etiology. As few papers have investigated its genetic, our aim was to evaluate HLA status in a single-center series of patients.Patients and method: A retrospective, longitudinal and cross-sectional study was conducted. Consecutive Caucasian patients, with clinical or histological diagnosis of primary autoimmune hypophysitis (PAH), undergone determination of HLA genotype, anti-pituitary ...

Introduction: Pasireotide Lar is a new generation long-acting somatostatin multireceptor ligand, approved for the treatment of first line somatostatin analogue resistant patients. We aimed to review Pasireotide Lar efficacy data, in our series of patients affected by aggressive acromegaly.Patients: A retrospective longitudinal study was conducted on patients with aggressive acromegaly, resistant to first-line somatostatin analogues (SSA) and on treatment...

Introduction: Infundibulo-neurohypophysitis (INH) is an uncommon inflammatory disorder. Because of the location of inflammation, it selectively affects the neuropituitary and pituitary stalk. The differential diagnosis remains often challenging with neoplastic lesions, such as germ cell neoplasia, Langerhans cell histiocytosis, Erdheim-Chester Disease, metastasis. Our clinical case is emblematic for pitfalls in diagnosis of the pituitary stalk lesionCase...